Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Alkermes plc

ALKSNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Jul 1, 2026Accepted Jul 1, 2026, 4:12 PM EDTFiling CIK 1520262Accession 0001964306-26-000304
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Alkermes plc.
Issuer CIK
0001520262
SEC file number
001-35299
Phone
00-353-1-772-8000
Person for whose account securities are to be sold
Hopkinson Craig C.
Relationships to issuer
Officer
Street
CONNAUGHT HOUSE
Street (continued)
1 BURLINGTON ROAD
City
DUBLIN 4
State / country code
L2
Postal code
00000

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Ordinary shares9,000463,620.68166,675,80707/01/2026NASDAQMerrill Lynch

Broker / market maker — proposed row 1, entry 1

Name
Merrill Lynch
Street
225 Liberty St
Street (continued)
Floor 37
City
New York
State / country code
NY
Postal code
10281

Acquisition of securities to be sold

Acquisition of securities to be sold · 2 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Ordinary shares07/01/2026Exercise of employee stock optionsAlkermes plc.5,000N07/01/2026Broker assisted cashless exercise
Ordinary shares02/05/2026Vesting of performance share awardAlkermes plc.4,000N02/05/2026Granted as part of issuer equity compensation plan

Sales reported in the preceding three months

Sales reported in the preceding three months · 4 reported rows
SellerSecuritySale dateAmount soldGross proceeds
Craig HopkinsonOrdinary shares03/02/20269,000267,485.14
Craig HopkinsonOrdinary shares04/01/20269,000319,604.00
Craig HopkinsonOrdinary Shares05/01/20269,000300,559.55
Craig HopkinsonOrdinary Shares06/01/20269,000375,043.23

Seller — prior-sale row 1, entry 1

Name
Craig Hopkinson
Street
CONNAUGHT HOUSE
Street (continued)
1 BURLINGTON ROAD
City
DUBLIN
State / country code
L2
Postal code
00000

Seller — prior-sale row 2, entry 1

Name
Craig Hopkinson
Street
CONNAUGHT HOUSE
Street (continued)
1 BURLINGTON ROAD
City
DUBLIN
State / country code
L2
Postal code
00000

Seller — prior-sale row 3, entry 1

Name
Craig Hopkinson
Street
CONNAUGHT HOUSE
Street (continued)
1 BURLINGTON ROAD
City
DUBLIN
State / country code
L2
Postal code
00000

Seller — prior-sale row 4, entry 1

Name
Craig Hopkinson
Street
CONNAUGHT HOUSE
Street (continued)
1 BURLINGTON ROAD
City
DUBLIN
State / country code
L2
Postal code
00000

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
07/01/2026
Signed
Craig Hopkinson
Plan adoption dates
03/14/2025

Company context

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Current securities

Recent company filings

  1. Regulation FD Disclosure · Other EventsSep 21, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 16, 2026
  3. 144 filingSep 3, 2026
  4. 144 filingSep 1, 2026
  5. Entry into a Material Definitive AgreementAug 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.